Novo Nordisk mim8 data near Jefferies’ ‘best’ case scenario

Jefferies says positive headline Phase 3 data for Novo Nordisk’s (NVO) mim8 in haemophilia A “may near our ‘best’ case scenario,” with convenient once-monthly dosing seeming similarly effective to once-weekly and efficacy data that may challenge Roche’s (RHHBY) incumbent Hemlibra. Based on the press release, the firm “could justify modest” Novo stock upside, Genmab (GMAB) shares being up 2%-4% and Roche shares being down 2%-3%, the analyst tells investors. Jefferies has an Underperform rating on Novo shares and Hold ratings on both Genmab and Roche.